

## Dear Shareholder

On behalf of the Board of AstraZeneca PLC (the Company), I am pleased to confirm that the Annual Report and Form 20-F Information 2020 (the Annual Report) has now been published, as well as the Notice of Annual General Meeting 2021 and Shareholders' Circular (the Notice of AGM).

The Company's 2021 Annual General Meeting (the AGM) will be a closed meeting due to UK Government COVID-19 restrictions relating to indoor gatherings and will be preceded by an online shareholder engagement event, as set out below.

- > The Company will hold an online shareholder engagement event on Friday 30 April 2021, consisting of a live-broadcast presentation from certain members of the Board. Shareholders are invited to participate in a Q&A session, should they wish to do so.
- > The AGM will be held on Tuesday 11 May 2021 as a closed meeting. No shareholder attendance will be permitted. Shareholders are strongly encouraged to vote in advance of the meeting by appointing the Chairman of the AGM as their proxy. The Chairman of the AGM will be able to vote on their behalf, and in accordance with their instructions, at the AGM.

More details about these arrangements can be found within the Notice of AGM.

## What you should have received

If you have previously requested paper copies of the Annual Report and the Notice of AGM, you will find paper copies enclosed. If you have previously elected to receive these documents via the AstraZeneca website, you can now access the Annual Report at, [www.astrazeneca.com/annualreport2020](http://www.astrazeneca.com/annualreport2020) and the Notice of AGM at, [www.astrazeneca.com/noticeofmeeting2021](http://www.astrazeneca.com/noticeofmeeting2021)

An 'at a glance' summary of the Company's performance during 2020 is included on pages 2 and 3 of this document. Useful information for shareholders is set out on page 4.

## Communicating with you

I would urge shareholders who currently receive communications from the Company in hard copy to consider opting to receive all future information from the Company in electronic format. There are clear environmental benefits and cost savings arising from reduced paper usage, printing and distribution if you do so.

You can elect to receive shareholder communications in electronic format by registering your details at, [www.shareview.co.uk](http://www.shareview.co.uk) and electing for e-communications. Whenever shareholder communications are published, we will send you an email with a link to the information on the AstraZeneca website.

I will be writing to you in due course with regards to the proposed acquisition by the Company of Alexion Pharmaceuticals Inc., which will require approval at a shareholders' general meeting.

Yours faithfully



## Leif Johansson

Chairman  
30 March 2021

## Important information

This document contains certain statements extracted from the Annual Report and Form 20-F Information 2020 (Annual Report) for AstraZeneca PLC that are neither reported financial results nor other historical information. These statements are forward-looking statements, including within the meaning of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those disclosed in our forward-looking statements. For a description of factors that could affect future results, reference should be made to the full 'Cautionary statement' on page 284 of the Annual Report and to the section entitled 'Risk' from page 254. This information is provided solely for the convenience of current and future members of the Company and is not intended to satisfy any statutory and/or regulatory requirements in the UK or elsewhere. Accordingly, it should only be read in conjunction with the Annual Report. The Company, its subsidiaries, Directors and officers shall not be liable for the consequence of any action taken solely in reliance on the information contained in this document.

Inspired by our Values and what science can do, we are focused on accelerating the delivery of life-changing medicines that create enduring value for patients and society.

**Key:**

CER – constant exchange rate.

Figures in parentheses are used to represent negative numbers.

Terms used in this 'at a glance' are as defined within the Annual Report.

**Our strategic priorities**

Our priorities reflect how we are working to deliver our growth through innovation strategy and achieve our Purpose: to push the boundaries of science to deliver life-changing medicines.



- 1. Deliver Growth and Therapy Area Leadership
- 2. Accelerate Innovative Science
- 3. Be a Great Place to Work

**A science-led value proposition**

**Distinctive R&D capabilities**

Small molecules, biologics, protein engineering and innovative delivery devices, as well as new scientific modalities, new technologies and new biology.

**171**  
projects in our development pipeline



**Strategic R&D centres**

- 1. Cambridge, UK (HQ)
- 2. Gaithersburg, MD, US
- 3. Gothenburg, Sweden

**Other R&D centres and offices**

- 4. South San Francisco, CA, US
- 5. Boston, MA, US
- 6. New York, NY, US
- 7. Alderley Park and Macclesfield, UK
- 8. Shanghai, China
- 9. Osaka, Japan

**Focus on three main therapy areas**

**Oncology**

Our ambition is to provide cures for cancer in every form. We are following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential for cure.

**Cardiovascular, Renal & Metabolism**

Our mission is to protect the lives of people from the consequences of CVRM diseases. We are committed to their seamless management, improving patient outcomes and decreasing the mortality rate.

**Respiratory & Immunology**

We aim to transform the treatment of R&I diseases, with the bold ambition to eliminate preventable attacks and achieve durable remission or even cure for millions of people with these potentially devastating conditions.

**Other Medicines and COVID-19**

We have medicines and vaccines in other disease areas that have an important impact for patients. We are working to defeat the COVID-19 pandemic by advancing and accelerating the development of potential medicines.

**Diversified portfolio of specialty and primary care medicines (Product Sales)**

**\$10,850m**

42% of total

2019: \$8,667m

2018: \$6,028m

Sales growth of 25% (26% at CER)

**\$7,096m**

27% of total

2019: \$6,906m

2018: \$6,710m

Sales growth of 3% (5% at CER)

**\$5,357m**

21% of total

2019: \$5,391m

2018: \$4,911m

Sales decline of 1% (0% at CER)


**\$2,587m**

10% of total


2019: \$2,601m

2018: \$3,400m


Sales decline of 1% (0% at CER)



Oncology.



Cardiovascular, Renal & Metabolism.



Respiratory & Immunology.

**Global strength, balanced presence across regions (Product Sales)**

**Emerging Markets**

**\$8,679m**

34% of total  
2019: \$8,165m  
2018: \$6,891m

Sales growth of 6%  
(10% at CER)

**US**

**\$8,638m**

33% of total  
2019: \$7,747m  
2018: \$6,876m

Sales growth of 12%  
(12% at CER)

**Europe**

**\$5,059m**

20% of total  
2019: \$4,350m  
2018: \$4,459m

Sales growth of 16%  
(15% at CER)

**Established Rest of World**

**\$3,514m**

14% of total  
2019: \$3,303m  
2018: \$2,823m

Sales growth of 6%  
(6% at CER)

**Commitment to people**

A focus on inclusion and diversity, as well as life-long learning and development.

**76,100**

employees  
2019: 70,600  
2018: 64,600

**46.9%**

of our senior roles are filled by women

**92%**

of employees believing strongly in AstraZeneca's future direction and key priorities

**81%**

of employees believing there is effective collaboration between teams

**Commitment to society**

Improving access to healthcare, environmental protection and ethics and transparency, including delivering our Ambition Zero Carbon programme.

**Priority**

**1**

Access to healthcare

**Priority**

**2**

Environmental protection

**Priority**

**3**

Ethics and transparency

**87%**

of employees saying they understand their contribution to our sustainability priorities



7th overall



A List for Climate and Water Security



World and Europe constituent



Index Series constituent

**Capital allocation priorities**

After providing for investment in the business, supporting the progressive dividend policy and maintaining a strong, investment-grade credit rating, we keep under review potential investment in immediately earnings-accretive, value-enhancing opportunities.

**Dividends**

**\$3,572m**

2019: \$3,592m  
2018: \$3,484m

**R&D expenditure (Reported)**

**\$5,991m**

2019: \$6,059m  
2018: \$5,932m

**Credit rating (Standard & Poor's)**

**BBB+**

Long term:  
CreditWatch  
Positive outlook

**Credit rating (Moody's)**

**A3**

Long term:  
Negative outlook

**Comprehensive response to the COVID-19 pandemic**

Our response was consistent with our Values of following the science, putting patients first and doing the right thing.

Helped ensure the safety of patients and their continued access to care and medicines.

Protected our employees and critical operations to ensure the continued supply of our medicines.

Contributed to the process of scientific innovation to combat the virus.

Contributed more broadly to society, including emergency relief.

# Dividends and other important information for shareholders

## Dividend payment and dates

The record date for the second interim dividend for 2020, payable on 29 March 2021, was 26 February 2021. The ex-dividend date was 25 February 2021. The record date for the first interim dividend for 2021, payable 13 September 2021, will be 13 August 2021 and the ex-dividend date will be 12 August 2021. Future dividends will normally be paid as follows:

First interim: announced in July/August and paid in September. Second interim: announced in January/February and paid in March.

Shareholders holding Ordinary Shares directly may opt for dividends to be paid straight to their bank or building society account, rather than being paid by cheque. To elect for this swift and secure method of payment, contact the Ordinary Share Registrar, visit Shareview using the link provided below, or fill in and return the mandate form sent to you with your AstraZeneca dividend cheque.

## Results

Unaudited trading results of AstraZeneca in respect of the first three months of 2021 will be published on 30 April 2021 and results in respect of the first six months of 2021 will be published on 29 July 2021.

## Shareview

Holders of Ordinary Shares may create a portfolio at, [www.shareview.co.uk](http://www.shareview.co.uk) to view and manage their AstraZeneca shareholding. Shareview is a free and secure online service provided by the Ordinary Share Registrar that allows users to, among other things, update personal details, manage communication preferences, view dividend information and manage direct dividend payments.

## ShareGift

Shareholders that hold only a small number of shares, the value of which makes it uneconomical to sell them, may wish to consider donating them to charity through ShareGift, an independent charity share donation scheme (registered charity number 1052686). Further information about ShareGift can be found on its website at, [www.sharegift.org](http://www.sharegift.org) or by calling +44 (0)20 7930 3737.

## Shareholder fraud warning

Shareholders of AstraZeneca and many other companies have reported receiving unsolicited calls and correspondence relating to their shareholdings and investment matters. Shareholders are advised to be very cautious of any unsolicited approaches and to note that reputable firms authorised by the Financial Conduct Authority (FCA) are very unlikely to make such approaches. Such approaches are likely to be part of a 'boiler room scam' attempting to defraud shareholders.

Shareholders are advised to familiarise themselves with the information on scams available on the FCA website, [www.fca.org.uk/consumers](http://www.fca.org.uk/consumers) and within the FAQ in the Investors section of AstraZeneca's website, [www.astrazeneca.com](http://www.astrazeneca.com).

Any suspected scams or fraudulent approaches should be reported to the FCA via its website and to AstraZeneca's Ordinary Share Registrar, using the contact details on this page.

## Registered office

AstraZeneca PLC  
1 Francis Crick Avenue  
Cambridge Biomedical Campus  
Cambridge CB2 0AA  
UK  
Tel: +44 (0)20 3749 5000

## Investor relations

UK: as above

US

Tel: (toll free in the US)  
+1 (866) 381 7277

## Ordinary Share Registrar

Equiniti  
Aspect House  
Spencer Road  
Lancing  
West Sussex BN99 6DA  
UK  
Tel: (freephone in the UK)  
0800 389 1580  
Tel: (outside the UK)  
+44 (0)121 415 7033

## Swedish Central Securities Depository

Euroclear Sweden AB  
PO Box 191  
SE-101 23 Stockholm  
Sweden  
Tel: +46 (0)8 402 9000

## US Depository

Deutsche Bank Trust Company Americas  
c/o American Stock Transfer  
6201 15th Avenue  
Brooklyn  
NY 11219  
USA  
Tel: (toll free in the US)  
888 697 8018  
Outside the US: +1 718 921 8137